These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
456 related items for PubMed ID: 16330292
1. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Cernea S, Kidron M, Wohlgelernter J, Raz I. Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292 [Abstract] [Full Text] [Related]
2. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772 [Abstract] [Full Text] [Related]
3. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S. Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286 [Abstract] [Full Text] [Related]
4. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Wutte A, Plank J, Bodenlenz M, Magnes C, Regittnig W, Sinner F, Rønn B, Zdravkovic M, Pieber TR. Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145 [Abstract] [Full Text] [Related]
5. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Diabetes Metab Res Rev; 2004 Jul; 20(6):472-8. PubMed ID: 15386822 [Abstract] [Full Text] [Related]
6. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098 [Abstract] [Full Text] [Related]
7. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR. Diabetologia; 2001 Mar; 44(3):305-8. PubMed ID: 11317660 [Abstract] [Full Text] [Related]
8. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977 [Abstract] [Full Text] [Related]
9. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T. Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911 [Abstract] [Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Hompesch M, Ocheltree SM, Wondmagegnehu ET, Morrow LA, Kollmeier AP, Campaigne BN, Jacober SJ. Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358 [Abstract] [Full Text] [Related]
11. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Korsatko S, Glettler K, Olsen KJ, Wutte A, Bock G, Koehler G, Mader JK, Semlitsch B, Pieber TR. Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357 [Abstract] [Full Text] [Related]
12. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30). Bott S, Tusek C, Heinemann L, Friberg HH, Heise T. Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159 [Abstract] [Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [Abstract] [Full Text] [Related]
14. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T. Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561 [Abstract] [Full Text] [Related]
15. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Krones R, Schütte C, Heise T. Diabetes Obes Metab; 2009 Jan; 11(1):41-4. PubMed ID: 19120432 [Abstract] [Full Text] [Related]
16. The effect of exercise on the absorption of inhaled human insulin via the AERx insulin diabetes management system in people with type 1 diabetes. Petersen AH, Köhler G, Korsatko S, Wutte A, Wonisch M, Jeppesen OK, Sparre T, Clauson P, Laursen T, Wollmer P, Pieber TR. Diabetes Care; 2007 Oct; 30(10):2571-6. PubMed ID: 17620446 [Abstract] [Full Text] [Related]
17. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH. Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120 [Abstract] [Full Text] [Related]
18. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Ocheltree SM, Hompesch M, Wondmagegnehu ET, Morrow L, Win K, Jacober SJ. Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081 [Abstract] [Full Text] [Related]
19. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154 [Abstract] [Full Text] [Related]
20. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ. Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011 [Abstract] [Full Text] [Related] Page: [Next] [New Search]